Mobocertinib succinate, developed by Takeda Oncology, represents an orally administered TKI strategically engineered to selectively act upon EGFR with Exon 20 insertion mutations identified in NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.